| Home : Oblique Therapeutics and Targovax Enter Collaboration to Target Mutant RAS Cancers by Combining Their ONCOS and Abiprot™ Platforms |
|
Jun 29
2020 |
Oblique Therapeutics and Targovax Enter Collaboration to Target Mutant RAS Cancers by Combining Their ONCOS and Abiprot™ Platforms |
|
Oblique Therapeutics and Targovax will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and AbiprotTM technology platforms ONCOS will be used to deliver AbiprotTM antibodies against hard-to-reach targets such as mutant RAS GOTHENBURG, Sweden and OSLO,... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/oblique-therapeutics-and-targovax-enter-collaboration-to-target-mutant-ras-cancers-by-combining-their-oncos-and-abiprot-platforms-301084831.html |
| |
|
Related News
|
» Xinhua Silk Road: online special feature on investment in south China's Hainan Jiangdong New Area launched
» Grand Canyon hiker died from suspected heat exposure: Park officials
|
